title: Antineoplastic effect of mer-trichlorobisdimethylsulphoxideaminorutheniumIII against murine tumors: comparison with cisplatin and with ImH[RuIm2Cl4].
abstract: An asymmetric rutheniumIII complex containing dimethylsulphoxide ligands, namely mer-trichlorobisdimethylsulphoxideaminorutheniumIII (BBR2382), has been tested in mice bearing solid metastasizing tumors. The effects of i.p. treatment with BBR2382 on primary tumor growth and on the survival time of hosts carrying s.c. or i.m. tumors have been compared to those of cisplatin and of a rutheniumIII complex with imidazole ligands, ImH[RuIm2Cl4], described as a potent antitumor agent in a number of experimental models of murine neoplasms. In mice bearing Lewis lung carcinoma, BBR2382 results as effective as cisplatin on s.c. primary tumor growth and more potent than cisplatin on the prolongation of host survival time. The combined treatment of mice bearing Lewis lung carcinoma with cisplatin and BBR2382 causes a reduction of s.c. tumors higher than that caused by each single agent; the effects on host survival time are similar to those caused by BBR2382 alone but significantly superior to those caused by cisplatin alone. In CBA mice bearing MCa mammary carcinoma, the effects of BBR2382 are slightly lower than those of cisplatin on i.m. tumors but are equivalent on host survival time. The comparison of the antineoplastic action of BBR2382 with that of ImH[RuIm2Cl4] is always in favor of the former, independently of the parameter chosen and of the tumor system used. Qualitatively, the antitumor action of BBR2382 seems different from that of cisplatin and of ImH[RuIm2Cl4]; it is supposed that this agent, like other "rutheniumIII dimethylsulphoxide" complexes, could have a particular efficacy for tumors localized in the lungs.
authors.affiliation: Institute of Pharmacology, School of Pharmacy, University of Trieste, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Pacor
authors.forename: G
authors.initials: G
authors.lastname: Sava
authors.forename: V
authors.initials: V
authors.lastname: Ceschia
authors.forename: F
authors.initials: F
authors.lastname: Bregant
authors.forename: G
authors.initials: G
authors.lastname: Mestroni
authors.forename: E
authors.initials: E
authors.lastname: Alessio
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents; D002277:Carcinoma / Q000188:drug therapy; D002945:Cisplatin / Q000627:therapeutic use; D007093:Imidazoles / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009942:Organometallic Compounds / Q000627:therapeutic use*; D012428:Ruthenium / Q000627:therapeutic use*; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D009942:Organometallic Compounds; C048589:imidazolium-bis(imidazole)tetrachlororuthenate(III); C069157:BBR 2382; D012428:Ruthenium; D002945:Cisplatin